Xiao B, Xu Z, Viennois E, et al
Many thanks also go to Bernard Thorens, Richard DiMarchi, Lotte Knudsen, John Eng, Jean-Pierre Raufman, Richard Goodman, Catherine rskov, Matthias Tschp, Daniel Drucker, Jesper Lau and Fred Cowan for their comments on various sections and providing permission to use their photos
A brand-new, March 2026 systematic review of semaglutide pancreatitis riskwhich is still in pre-print, and may not hold up to peer reviewconcluded semaglutide was not associated with an increased risk of acute pancreatitis compared to placebo
1 Factors that will affect the choice of the second agent include patient preference, cost, potential adverse effects, impact on weight, efficacy, and risk of hypoglycemia
Because their mechanisms do not overlap, stacking them creates a two-pronged approach: Retatrutide reduces caloric intake and boosts metabolic rate from the top down, while AOD-9604 attacks stored fat at the cellular level from the bottom up